CML-CP; Mutation;Suboptimal Response or Failure in TKI
1 clinical trials · Condition
◉ Watch CML-CP; Mutation;Suboptimal Response or Failure in TKI
| Record | Firm | Date |
|---|---|---|
| Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib (NCT04681820) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2020-11-01 |
Track CML-CP; Mutation;Suboptimal Response or Failure in TKI automatically
Every clearance here is in the API, with alerts when new ones post.